Fluorouracil 50 mg/mL · injectable solution
Misc., Injections & Implants
OFF-LABELNot in the FDA label for this product
Bleb needling after trabeculectomy
Subconjunctival 5-fluorouracil at the needling site, dose and concentration varying by protocol
NMA · no difference shown
A systematic review with network meta-analysis of needling revision compared mitomycin C, 5-fluorouracil and no antimetabolite at all. It found no significant difference between them in intraocular pressure at 12 months or latest follow-up, complication rates, qualified or complete success, or the number of re-needling cases. Six studies met inclusion and only one was randomized, and the authors attribute an overall low quality of evidence to that design mix and call for further research. So this is no difference SHOWN, not a difference ruled out.
Contraindications
None.
500 mg/10 mL (50 mg/mL) single dose vial, 1 g/20 mL (50 mg/mL) single dose vial, 10 vials per shelf pack
Fluorouracil is a nucleoside metabolic inhibitor that interferes with the synthesis of deoxyribonucleic acid (DNA) and to a lesser extent inhibits the formation of ribonucleic acid (RNA); these affect rapidly growing cells and may lead to cell death. Fluorouracil is converted to three main active metabolites: 5-fluoro-2′-deoxyuridine-5′-monophosphate (FdUMP), 5-fluorouridine-5′triphosphate (FUTP) and 5-fluoro-2′-deoxyuridine-5′-triphosphate (FdUTP). These metabolites have several effects including the inhibition of thymidylate synthase by FdUMP, incorporation of FUTP into RNA and incorporation of FdUTP into DNA.
Warnings & Precautions
- Increased Risk of Serious or Fatal Adverse Reactions: Patients with complete or near complete absence of dipyrimidine dehydrogenase (DPD) activity are at increased risk of severe, life-threatening, or fatal adverse reactions, and patients with partial DPD activity may also have increased risk. Withhold or permanently discontinue fluorouracil in patients with evidence of acute early-onset or unusually severe toxicity. No fluorouracil dose has been proven safe for patients with complete absence of DPD activity.
- Cardiotoxicity: Fluorouracil can cause cardiotoxicity, including angina, myocardial infarction/ischemia, arrhythmia, and heart failure. Withhold fluorouracil for cardiac toxicity.
- Hyperammonemic Encephalopathy: Altered mental status, confusion, disorientation, coma, or ataxia with elevated serum ammonia level can occur within 72 hours of initiation of fluorouracil. Withhold fluorouracil and initiate ammonia-lowering therapy.
- Neurologic Toxicity: Fluorouracil can cause acute cerebellar syndrome, confusion, disorientation, ataxia, or visual disturbances. Withhold fluorouracil for neurologic toxicity.
- Diarrhea: Fluorouracil can cause severe diarrhea. Withhold fluorouracil for severe diarrhea until resolved.
- Palmar-Plantar Erythrodysesthesia (Hand-Foot Syndrome): Fluorouracil can cause hand-foot syndrome. If severe, discontinue fluorouracil until resolved or decreased to Grade 1, then resume at a reduced dose.
- Myelosuppression: Fluorouracil can cause severe and fatal myelosuppression. Withhold fluorouracil until severe myelosuppression resolves, then resume at a reduced dose.
- Mucositis: Fluorouracil can cause severe mucositis. Withhold fluorouracil administration for Grade 3 or 4 mucositis; resume fluorouracil at a reduced dose once mucositis has resolved or decreased in severity to Grade 1.
- Increased Risk of Elevated INR with Warfarin: Clinically significant elevations in coagulation parameters have been reported during concomitant use of warfarin and fluorouracil. Closely monitor patients receiving concomitant coumarin-derivative anticoagulants such as warfarin for INR or prothrombin time in order to adjust the anticoagulant dose accordingly.
- Embryofetal Toxicity: Based on its mechanism of action, fluorouracil can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception during and for 3 months following cessation of therapy with fluorouracil.
Common Side Effects
Reported adverse reactions include increased risk of serious or fatal adverse reactions in patients with low or absent dipyrimidine dehydrogenase activity, cardiotoxicity, hyperammonemic encephalopathy, neurologic toxicity, diarrhea, palmar-plantar erythrodysesthesia (hand-foot syndrome), myelosuppression, mucositis, and increased risk of elevated INR when administrated with warfarin. Ophthalmic reactions identified during postapproval use include lacrimal duct stenosis, visual changes, lacrimation, and photophobia.
Pregnancy: There are no adequate and well-controlled studies with fluorouracil in pregnant women. Based on its mechanism of action, fluorouracil can cause fetal harm when administered to a pregnant woman.
Lactation: It is not known whether fluorouracil or its metabolites are present in human milk. Because of the potential for serious adverse reactions in nursing infants from fluorouracil, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
The safety and effectiveness in pediatric patients have not been established.